The 12-month forecast for Clovis Oncology Inc($CLVS) is out now

Market Data

Clovis Oncology Inc(CLVS) is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about CLVS. We will be studying the movement so you can make the best decision as an investor. The stock has moved upwards today by 1.70%. The high for today is 6.05 and today’s low is 5.75. This information is critical in deciding whether this investment is risky or not. We can see the stock is trending upwards, which means the volume of people buying this stock is greater than people selling it.

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Stock Forecast

As an investor, you can get an idea of where the stock is trending by the forecast. In this case, the high forecast for Clovis Oncology Inc is $13.00 and the low forecast is $9.50. Overall, Clovis Oncology Inc is in great shape going forward. They have a strong market cap of $624.25M and a very bright future ahead of them. Make sure to subscribe to our newsletter to never miss an update!

Leave a Reply

%d bloggers like this: